Skip to main content
To KTH's start page

Publications

The 50 latest publications

[1]
I. Zimmermann et al., "Immobilizing calcium-dependent affinity ligand onto iron oxide nanoparticles for mild magnetic mAb separation," Biotechnology Reports, vol. 45, 2025.
[2]
I. Zimmermann et al., "Calcium-dependent magnetic separation: A novel approach for the integrated processing of high-quality mAbs," Separation and Purification Technology, vol. 371, 2025.
[3]
C. Dahlsson Leitao et al., "The many virtues of staphylococcal protein A : A journey from N to C terminus," Journal of Biotechnology, vol. 406, pp. 272-280, 2025.
[4]
M. Möller et al., "Deep sequencing combined with high-throughput screening enables efficient development of a pH-dependent high-affinity binding domain targeting HER3," Protein Science, vol. 34, no. 8, 2025.
[5]
H. O. Masson et al., "Deciphering the determinants of recombinant protein expression across the human secretome," Proceedings of the National Academy of Sciences of the United States of America, vol. 122, no. 41, 2025.
[6]
M. Jönsson et al., "Engineered calcium-regulated affinity protein for efficient internalization and lysosomal toxin delivery," Proceedings of the National Academy of Sciences of the United States of America, vol. 122, no. 48, 2025.
[7]
J. Yan et al., "Distinct roles of vaccine-induced SARS-CoV-2-specific neutralizing antibodies and T cells in protection and disease," Molecular Therapy, vol. 32, no. 2, pp. 540-555, 2024.
[8]
O. Bragina et al., "Evaluation of Approaches for the Assessment of HER2 Expression in Breast Cancer by Radionuclide Imaging Using the Scaffold Protein [<sup>99m</sup>Tc]Tc-ADAPT6," Pharmaceutics, vol. 16, no. 4, 2024.
[9]
A. Wisniewski et al., "Targeted HER2-positive cancer therapy using ADAPT6 fused to horseradish peroxidase," New Biotechnology, vol. 83, pp. 74-81, 2024.
[10]
M. Jönsson et al., "The multifaceted usefulness of calcium-regulated affinity molecules," Journal of Peptide Science, vol. 30, 2024.
[11]
A. Jernbom Falk et al., "Prevalent and persistent new-onset autoantibodies in mild to severe COVID-19," Nature Communications, vol. 15, no. 1, 2024.
[12]
M. Jönsson et al., "Cooperative folding as a molecular switch in an evolved antibody binder," Journal of Biological Chemistry, vol. 300, no. 11, 2024.
[13]
M. Dannemeyer et al., "Fast and robust recombinant protein production utilizing episomal stable pools in WAVE bioreactors," Protein Expression and Purification, vol. 221, 2024.
[14]
U. Marking et al., "Humoral immune responses to the monovalent xbb.1.5-adapted bnt162b2 mrna booster in sweden," The Lancet - Infectious diseases, vol. 24, no. 2, pp. e80-e81, 2024.
[15]
J. Scheffel et al., "Calcium-dependent affinity ligands for the purification of antibody fragments at neutral pH," Journal of Chromatography A, vol. 1694, pp. 463902, 2023.
[16]
O. Bragina et al., "Direct Intra-Patient Comparison of Scaffold Protein-Based Tracers, [99mTc]Tc-ADAPT6 and [99mTc]Tc-(HE)3-G3, for Imaging of HER2-Positive Breast Cancer," Cancers, vol. 15, no. 12, 2023.
[17]
U. Marking et al., "Correlates of protection and viral load trajectories in omicron breakthrough infections in triple vaccinated healthcare workers," Nature Communications, vol. 14, no. 1, 2023.
[18]
U. Marking et al., "7-month duration of SARS-CoV-2 mucosal immunoglobulin-A responses and protection," The Lancet - Infectious diseases, vol. 23, no. 2, pp. 150-152, 2023.
[19]
A. Abouzayed et al., "The GRPR Antagonist [Tc-99m]Tc-maSSS-PEG(2)-RM26 towards Phase I Clinical Trial : Kit Preparation, Characterization and Toxicity," Diagnostics, vol. 13, no. 9, pp. 1611, 2023.
[20]
J. Nilvebrant, S. Hober and S. Kanje, "Ligand and use thereof," us 11820802 (2023-11-21), 2023.
[21]
M. Möller et al., "An easy-to-use high-throughput selection system for the discovery of recombinant protein binders from alternative scaffold libraries," Protein Engineering Design & Selection, vol. 36, 2023.
[22]
M. Wolf-Watz et al., "Calcium-dependent protein folding in a designed molecular switch," Biophysical Journal, vol. 122, no. 3S1, 2023.
[23]
O. Bladh et al., "Mucosal immune responses following a fourth SARS-CoV-2 vaccine dose," The Lancet Microbe, vol. 4, no. 7, pp. 488, 2023.
[24]
J. Scheffel et al., "Design of an integrated continuous downstream process for acid-sensitive monoclonal antibodies based on a calcium-dependent Protein A ligand," Journal of Chromatography A, vol. 1664, pp. 462806-462806, 2022.
[25]
L. Blixt et al., "Covid-19 in patients with chronic lymphocytic leukemia : clinical outcome and B- and T-cell immunity during 13 months in consecutive patients," Leukemia, vol. 36, no. 2, pp. 476-481, 2022.
[26]
I. Lauren et al., "Long-term SARS-CoV-2-specific and cross-reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology," Immunity, Inflammation and Disease, vol. 10, no. 4, 2022.
[27]
U. Marking et al., "Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines," Vaccines, vol. 10, no. 3, pp. 359, 2022.
[28]
S. Havervall et al., "Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time," Clinical & Translational Immunology (CTI), vol. 11, no. 4, 2022.
[29]
K. Asplund Högelin et al., "B-cell repopulation dynamics and drug pharmacokinetics impact SARS-CoV-2 vaccine efficacy in anti-CD20-treated multiple sclerosis patients," European Journal of Neurology, vol. 29, no. 11, pp. 3317-3328, 2022.
[30]
S. Appelberg et al., "A universal SARS-CoV DNA vaccine inducing highly cross-reactive neutralizing antibodies and T cells," EMBO Molecular Medicine, vol. 14, no. 10, 2022.
[31]
S. Havervall et al., "Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection," New England Journal of Medicine, vol. 387, no. 14, pp. 1333-1336, 2022.
[32]
S. Havervall et al., "SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection," PLOS ONE, vol. 17, no. 1, pp. e0262169-e0262169, 2022.
[33]
S. Havervall et al., "Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19," Journal of Internal Medicine, vol. 291, no. 1, pp. 72-80, 2022.
[34]
K. Healy et al., "Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individuals," MED, vol. 3, no. 2, pp. 137-153, 2022.
[35]
H. Schwarz et al., "Integrated continuous biomanufacturing on pilot scale for acid-sensitive monoclonal antibodies," Biotechnology and Bioengineering, 2022.
[36]
V. Tolmachev et al., "Direct In Vivo Comparison of Tc-99m-Labeled Scaffold Proteins, DARPin G3 and ADAPT6, for Visualization of HER2 Expression and Monitoring of Early Response for Trastuzumab Therapy," International Journal of Molecular Sciences, vol. 23, no. 23, 2022.
[37]
J. Garousi et al., "Experimental HER2-Targeted Therapy Using ADAPT6-ABD-mcDM1 in Mice Bearing SKOV3 Ovarian Cancer Xenografts : Efficacy and Selection of Companion Imaging Counterpart," Pharmaceutics, vol. 14, no. 8, 2022.
[38]
M. Malm et al., "Harnessing secretory pathway differences between HEK293 and CHO to rescue production of difficult to express proteins," Metabolic engineering, vol. 72, pp. 171-187, 2022.
[39]
K. Blom et al., "Immune responses after omicron infection in triple-vaccinated health-care workers with and without previous SARS-CoV-2 infection," The Lancet - Infectious diseases, vol. 22, no. 7, pp. 943-945, 2022.
[40]
S. Mravinacová et al., "A cell-free high throughput assay for assessment of SARS-CoV-2 neutralizing antibodies," New Biotechnology, vol. 66, pp. 46-52, 2022.
[41]
C. Ekblad et al., "Polypeptides based on a scaffold," us 11505576 (2022-11-22), 2022.
[42]
M. Jönsson et al., "CaRA – A multi-purpose phage display library for selection of calcium-regulated affinity proteins," New Biotechnology, vol. 72, pp. 159-167, 2022.
[43]
K. M. Elfstrom et al., "Differences in risk for SARS-CoV-2 infection among healthcare workers," Preventive Medicine Reports, vol. 24, 2021.
[44]
S. M. Mangsbo et al., "An evaluation of a FluoroSpot assay as a diagnostic tool to determine SARS-CoV-2 specific T cell responses," PLOS ONE, vol. 16, no. 9, 2021.
[45]
P. Bergman et al., "Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial," EBioMedicine, vol. 74, pp. 103705, 2021.
[46]
O. Bragina et al., "Phase I Study of Tc-99(m)-ADAPT6, a Scaffold Protein-Based Probe for Visualization of HER2 Expression in Breast Cancer," Journal of Nuclear Medicine, vol. 62, no. 4, pp. 493-499, 2021.
[47]
J. Dillner et al., "High Amounts of SARS-CoV-2 Precede Sickness Among Asymptomatic Health Care Workers," The Journal of Infectious Diseases, vol. 224, no. 1, pp. 14-20, 2021.
[48]
J. Garousi et al., "Radionuclide therapy using ABD-fused ADAPT scaffold protein : Proof of Principle," Biomaterials, vol. 266, 2021.
[49]
K. A. Högelin et al., "Development of humoral and cellular immunological memory against SARS-CoV-2 despite B cell depleting treatment in multiple sclerosis," iScience, vol. 24, no. 9, 2021.
[50]
S. Havervall et al., "Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2," EBioMedicine, vol. 70, 2021.